Close

AVEO Oncology (AVEO) Reports Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. ENPH
3. TXN
4. BA
5. SPOT
6. META
7. V
8. IBM
9. KMB
10. GM


Go back to AVEO Oncology (AVEO) Reports Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

AVEO Oncology (AVEO) Set to Open Higher Following Data

September 10, 2019 7:54 AM EDT

AVEO Oncology (NASDAQ: AVEO) was set to open higher Tuesday after it reported results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. The stock gained 20%.

... More